WO1994018961A1 - Cancer treatment - Google Patents

Cancer treatment Download PDF

Info

Publication number
WO1994018961A1
WO1994018961A1 PCT/CA1994/000087 CA9400087W WO9418961A1 WO 1994018961 A1 WO1994018961 A1 WO 1994018961A1 CA 9400087 W CA9400087 W CA 9400087W WO 9418961 A1 WO9418961 A1 WO 9418961A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
compound
cells
cancer cells
tricyclic
Prior art date
Application number
PCT/CA1994/000087
Other languages
English (en)
French (fr)
Inventor
Lorne J. Brandes
Ron Reid
Original Assignee
University Of Manitoba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Manitoba filed Critical University Of Manitoba
Priority to AU60352/94A priority Critical patent/AU693780B2/en
Priority to EP94906813A priority patent/EP0684817A1/en
Priority to CA002156162A priority patent/CA2156162C/en
Priority to KR1019950703444A priority patent/KR960700698A/ko
Publication of WO1994018961A1 publication Critical patent/WO1994018961A1/en
Priority to US08/773,987 priority patent/US6284799B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/20—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/22—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by carbon atoms having at least two bonds to oxygen atoms

Definitions

  • the present invention is concerned with the identification of compounds which increase the therapeutic index of chemotherapy drugs and which stimulate the growth of cancers, their use in the treatment of cancer and with certain novel compounds useful in such treatment.
  • phenothiazines are known to be antagonists of dopamine (D 2 ) receptors
  • interactions at many other intracellular sites, including calmodulin, protein kinase C and calcium channels may be important to their activity.
  • antidepressants are known to decrease the uptake of biogenic amine neurotransmitters into nerve endings (especially serotonin and norepinephrine) thereby increasing their concentration in synapses, a good correlation between potency to inhibit the uptake of any specific amine and potency as antidepressant agents has not been shown.
  • H IC histamine receptors
  • DPPE phenylmethyl-phenoxy] -ethanamine.HCl
  • H IC phenothiazines
  • x antagonists phenothiazines
  • serotonin (5HT- L , and 5HT 3 ) antagonists triphenylethylene antiestrogens and /3-adrenergic antagonists
  • H 2 antagonists and other imidazoles do not compete for DPPE binding, they do compete for H IC , but with lower affinity than for compounds which bind both AEBS and H IC .
  • H IC histamine functions as an intracellular messenger to mediate aggregation in blood platelets and is implicated in the proliferation of normal and malignant cells.
  • a second messenger role for histamine at H IC also has been postulated in estrogen action and in brain function.
  • H IC binding may be common to the action of many classe" of drugs, including phenothiazines, antidepressants, antiestrogens, histamine (H 1; H 2 , H 3 ) antagonists, serotonin (5HT- L , 5HT 3 ) antagonists, /3-adrenergic antagonists and antifungal agents.
  • DPPE also directly cytoprotects normal gut mucosa in vitro, an effect related to DPPE-induced increases in endogenous levels of the protective prostaglandin, PGI 2 and reversed by indomethicin.
  • tricyclic antidepressant drugs and the non-tricyclic agent, fluoxetine (ProzacTM) as well as H- L -antihistamines and ⁇ - adrenergic antagonists, also compete for the binding of 3 H-DPPE and 3 H-histamine to H IC in rat liver microsomes or brain membranes and, likewise, promote tumor growth.
  • fluoxetine ProzacTM
  • H- L -antihistamines and ⁇ - adrenergic antagonists also compete for the binding of 3 H-DPPE and 3 H-histamine to H IC in rat liver microsomes or brain membranes and, likewise, promote tumor growth.
  • a method for the treatment of cancer cells in an animal which comprises:
  • Such compounds may be prepared by any convenient procedure depending on the identity of the variable groups.
  • the compound may be made by reacting a hydroxy substituted fluoro-benzophenone with a chloro-substituted amino-substitute alkyl group.
  • Figures 1 to 10 are graphical representations of text data generated in certain experiments set forth in the Examples below.
  • any compound which inhibits normal cell proliferation while promoting malignant cell proliferation is useful and is administered in an amount sufficient to inhibit the binding of intracellular histamine in normal cells.
  • Such compounds generally exhibit a pKi of at least about 5, preferably at least about 5.5.
  • X and Y are each fluorine, chlorine or bromine
  • o and p are 0 or 1
  • R x and R 2 are each alkyl groups containing 1 to 3 carbon atoms or are joined together tc form a hetero-ring with the nitrogen atoms and n is 1, 2 or 3.
  • Pharmaceutically-acceptable salts of the diphenyl compounds may be employed.
  • benzene rings may be joined to form a tricyclic ring, in accordance with the structure:
  • n, R- t and R 2 are as described above.
  • o and p are usually 0 when Z is an alkylene group and n may be 2. In one particularly preferred embodiment of the compounds of formula I, Z is -CH 2 -, n is 2, o and p are each 0 and
  • n 2 and
  • DFPE diethylamino group.
  • This compound exhibits a potency of two to four times that of DPPE in inhibiting normal cell proliferation and promoting malignant cell proliferation in H IC binding competition assays.
  • tricyclic antidepressants e.g. amitriptyline, clomipramine, imipramine and like agents
  • non-tricyclic antidepressants e.g. fluoxetine and like agents
  • phenothiazines e.g. prochlorperazine, trifluoroperizine, chlorpromazine and like agents
  • H- L -antihistamines e.g., loratadine, hydroxyzine, phenyltoloxamine, astemizole and the like
  • imidazoles and imidazole-like compounds including H 2 antagonists, such as cimetidine and ranitidine, H 3 antagonists, such as thioperamide and antifungal agents, such as ketoconazole, and (h) triphenylethylene derivatives, such as tamoxifen.
  • H 2 antagonists such as cimetidine and ranitidine
  • H 3 antagonists such as thioperamide and antifungal agents, such as ketoconazole
  • triphenylethylene derivatives such as tamoxifen.
  • the compounds which may be employed may have a chemical structure consisting of at least two phenyl rings, linked by a rigid third phenyl or non- phenyl ring, or by a non-rigid methyl, oxygen, or other moiety, with the phenyl ring structure being linked by an ether, sulfhydryl or other ring structure or group to a basic alkylamine or imidazole or amino-imidazole side chain, for example, the carboxyamide-amino-imidazole L651582.
  • DPPE and its direct analogs may be a significantly better agent for combination with chemotherapy agents than the foregoing groups of compounds, since DPPE appears to be more potent and selective for H IC and does not interact with calmodulin, protein kinase C, or calcium channels and is only a weak antagonist at other common receptors, such as E l r 5HT and D 2 .
  • DPPE does not cause serious toxic effects in humans at clinically relevant doses to enhance chemotherapy (about 0.2-12 mg/kg, preferably less than about 10 mg/kg, with about 6 mg being an optimal dose)
  • the antidepressant group of drugs may cause cardiac arrythmias
  • x antagonists might cause marked sedation or even convulsions
  • phenothiazines may cause dyskenesias.
  • FIG. 1 shows the tumor-promoting effect DPPE (1 mg/kg or 4 mg/M 2 ) given subcutaneously once daily x 3, to seven DBA/2 mice inoculated subcutaneously with 2 x 10 2 L5178Y lymphoma cells 48 hours previously.
  • a second group of 7 tumor cell-inoculated mice served as controls (saline injections, once daily x 3) .
  • 7/7 DPPE treated animals had palpable tumors as compared to 4/7 controls.
  • mice DBA/2 mice
  • groups of 3 animals were shaved over the back and 48 hours later received a single topical application of 17 nM PMA in acetone.
  • the PMA-treated mice then received either saline (control) or DPPE (4 or 32 mg/kg at time 0 and 24 hours) .
  • Three animals painted with acetone served as vehicle controls. Forty-eight hours later, the various groups were sacrificed by C0 2 asphyxiation, the skin carefully excised, pinned to paper strips to prevent wrinkling, and immersed in formaldehyde. H and E-stained sections of skin were assessed for degree of inflammation.
  • FIG. 2 shows the potency of two tricyclic agents, namely amitriptyline and doxepin, to compete for 3 H-DPPE binding in liver microsomes.
  • the K d value for DPPE is 65 nM while the K ⁇ for doxepin is 5 ⁇ M and for amitriptyline is 10 ⁇ M.
  • Figure 4 demonstrates the tumor-promoting effects of the tricyclic agent, amitriptyline, and the non-tricyclic agent, fluoxetine, in C3H mice injected subcutaneously into the gluteal region with 1 x 10 5 C-3 fibrosarcoma cells.
  • the doses employed were equivalent to therapeutic human doses (80 mg/M 2 for amitriptyline and 20-40 mg/M 2 for fluoxetine) .
  • IC 50 10 to 20 ⁇ M
  • Figure 6A shows that propanolol (a ⁇ -adrenergic antagonist) inhibits histamine binding to H IC in microsomes and Fig re 6B shows that propanolol inhibits normal lymphocyte mitogenesis.
  • propanolol significantly increased tumor weight on Day 23, as seen in Figure 7.
  • the morpholino-analogue also was prepared using the above-described procedure, but substituting 4- (2- chloroethyDmorpholine.HCl for DEAE.HC1.
  • Example IV This Example illustrates the binding characteristics and antiproliterative properties of DPPE.
  • DFPE competes for [ 3 H] DPPE binding in rat liver microsomes with a K t value of approximately 70 nM.
  • Ki value for DFPE approximates the K d value for DPPE in the same assay.
  • DFPE competes for [ 3 H] histamine binding in rat cortical membranes with a K ⁇ value of 0.3 x 10 "6 M.
  • DFPE is approximately three times moire potent than DPPE in inhibiting histamine binding at a non-H 1# non-H 2 site (H IC ) in brain membranes (Brandes,
  • PMA phorbol myristate acetate
  • DFPE and DPPE The ability of DFPE and DPPE to inhibit/kill the growth of MCF-7 human breast cancer cells after seven days incubation at 37°C in vitro is shown in Figure 10.
  • the IC 50 value for DFPE is 3.0 x 10 "6 M. This compares with an IC 50 value for DPPE of 6.5 x 10 "6 in the same assay.
  • DFPE possesses novel antihistaminic properties, antagonizes the effects of phorbol myristate acetate on platelet aggregation, and is antiproliferative cyclotoxic to MCF-7 human breast cancer cells, all with a potency approximately three to four times greater than that of DPPE. Since DPPE has been demonstrated to be antiestrogenic in vivo, to augment the effects of tamoxifen in the rat uterus in vivo, a similar spectrum of in vivo activity is expected for DFPE, but with an overall potency two to four fold greater than that observed for DPPE. In addition DFPE may be used in place of DPPE in the cancer treatment method described herein to improve the therapeutic index of conventional chemotherapy drugs.
  • the present invention provides identification of compounds and classes of compounds which stimulate cancer growth and which enable the therapeutic index of chemotherapy agents to be improved. Novel compounds also are described. Modifications are possible within the scope of this invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/CA1994/000087 1993-02-17 1994-02-17 Cancer treatment WO1994018961A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU60352/94A AU693780B2 (en) 1993-02-17 1994-02-17 Cancer treatment
EP94906813A EP0684817A1 (en) 1993-02-17 1994-02-17 Cancer treatment
CA002156162A CA2156162C (en) 1993-02-17 1994-02-17 Cancer treatment
KR1019950703444A KR960700698A (ko) 1993-02-17 1994-02-17 암 치료제(cancer treatment)
US08/773,987 US6284799B1 (en) 1994-02-17 1996-12-26 Cancer treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9303210.0 1993-02-17
GB939303210A GB9303210D0 (en) 1993-02-17 1993-02-17 Cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US50526996A Continuation 1994-02-17 1996-02-23

Publications (1)

Publication Number Publication Date
WO1994018961A1 true WO1994018961A1 (en) 1994-09-01

Family

ID=10730606

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1994/000087 WO1994018961A1 (en) 1993-02-17 1994-02-17 Cancer treatment

Country Status (6)

Country Link
EP (1) EP0684817A1 (ja)
JP (2) JP2834328B2 (ja)
KR (1) KR960700698A (ja)
AU (2) AU693780B2 (ja)
GB (1) GB9303210D0 (ja)
WO (1) WO1994018961A1 (ja)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017887A1 (en) * 1993-12-27 1995-07-06 University Of Manitoba Method of treatment of hormone-unresponsive metastatic prostate cancer
WO1996010999A2 (en) * 1994-10-11 1996-04-18 G.D. Searle & Co. Lta4 hydrolase inhibitor pharmaceutical compositions and methods of use
US5719306A (en) * 1994-10-11 1998-02-17 G.D. Searle & Co. LTA4 hydrolase inhibitors
WO1998006394A1 (en) * 1996-08-16 1998-02-19 Schering Corporation Treatment of upper airway allergic responses with a combination of histamine receptor antagonists
US5869479A (en) * 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses
WO2003022258A1 (en) * 2001-09-10 2003-03-20 Ramot At Tel Aviv University Ltd. Aryloxypropylamines as chemosensitizing agent in the treatment of cancer
EP1347752A2 (en) * 2000-11-29 2003-10-01 Ramot at Tel-Aviv University Ltd. Anti-proliferative drugs
US6638736B1 (en) 1998-04-21 2003-10-28 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Human K+ ion EAG channels
WO2004022040A2 (en) * 2002-09-04 2004-03-18 The University Of Manitoba Treatment of metastatic breast cancer with anthracyclines, taxanes and an histamine antagonist
WO2012092114A2 (en) 2010-12-27 2012-07-05 The Curators Of The University Of Missouri Oxidosqualene cyclase as a protein target for anticancer therapeutics
US10456388B2 (en) 2015-01-19 2019-10-29 Belina Pharma Ab Antihistamine for use in treatment of breast cancer

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102312100B1 (ko) * 2020-06-05 2021-10-14 (주)프론트바이오 항바이러스제 및 항우울제를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
KR20230018341A (ko) * 2021-07-29 2023-02-07 (주)프론트바이오 항바이러스제 및 항우울제를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3288806A (en) * 1964-03-23 1966-11-29 Parke Davis & Co Alpha-(aminoethoxyphenyl)-alpha-alkylstilbenes
EP0114410A1 (de) * 1982-12-28 1984-08-01 Richter Gedeon Vegyeszeti Gyar R.T. Substituierte alpha-(Äthyl)-alpha-(phenyl)-(omega-(dialkylamino)-alkoxy)-benzylalkohole, ihre Säureadditionssalze und quaternären Salze, Verfahren zu ihrer Herstellung sowie diese Verbindungen enthaltende Arzneimittel
EP0115079A1 (de) * 1982-12-28 1984-08-08 Richter Gedeon Vegyeszeti Gyar R.T. Substituierte 1-((3-(Amino)-propoxy)-phenyl)-1-(phenyl)-propan-1-ole, ihre Säureadditionssalze und quaternären Salze, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0115205A1 (en) * 1982-12-28 1984-08-08 Richter Gedeon Vegyészeti Gyár R.T. Aminoethoxybenzylalcohol derivatives, process for their preparation and pharmaceutical compositions containing them
EP0115080A1 (de) * 1982-12-28 1984-08-08 Richter Gedeon Vegyeszeti Gyar R.T. (Omega-(Diäthylamino)-alkoxy)-alpha-(äthyl)-benzhydrolderivate, ihre Säureadditionssalze und quaternären Salze, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
WO1992011035A1 (en) * 1990-12-17 1992-07-09 University Of Manitoba Improved treatment method for cancer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3288806A (en) * 1964-03-23 1966-11-29 Parke Davis & Co Alpha-(aminoethoxyphenyl)-alpha-alkylstilbenes
EP0114410A1 (de) * 1982-12-28 1984-08-01 Richter Gedeon Vegyeszeti Gyar R.T. Substituierte alpha-(Äthyl)-alpha-(phenyl)-(omega-(dialkylamino)-alkoxy)-benzylalkohole, ihre Säureadditionssalze und quaternären Salze, Verfahren zu ihrer Herstellung sowie diese Verbindungen enthaltende Arzneimittel
EP0115079A1 (de) * 1982-12-28 1984-08-08 Richter Gedeon Vegyeszeti Gyar R.T. Substituierte 1-((3-(Amino)-propoxy)-phenyl)-1-(phenyl)-propan-1-ole, ihre Säureadditionssalze und quaternären Salze, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0115205A1 (en) * 1982-12-28 1984-08-08 Richter Gedeon Vegyészeti Gyár R.T. Aminoethoxybenzylalcohol derivatives, process for their preparation and pharmaceutical compositions containing them
EP0115080A1 (de) * 1982-12-28 1984-08-08 Richter Gedeon Vegyeszeti Gyar R.T. (Omega-(Diäthylamino)-alkoxy)-alpha-(äthyl)-benzhydrolderivate, ihre Säureadditionssalze und quaternären Salze, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
WO1992011035A1 (en) * 1990-12-17 1992-07-09 University Of Manitoba Improved treatment method for cancer

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017887A1 (en) * 1993-12-27 1995-07-06 University Of Manitoba Method of treatment of hormone-unresponsive metastatic prostate cancer
WO1996010999A2 (en) * 1994-10-11 1996-04-18 G.D. Searle & Co. Lta4 hydrolase inhibitor pharmaceutical compositions and methods of use
WO1996010999A3 (en) * 1994-10-11 1996-09-19 Searle & Co Lta4 hydrolase inhibitor pharmaceutical compositions and methods of use
US5719306A (en) * 1994-10-11 1998-02-17 G.D. Searle & Co. LTA4 hydrolase inhibitors
US5723492A (en) * 1994-10-11 1998-03-03 G.D. Searle & Co. LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use
US6506876B1 (en) 1994-10-11 2003-01-14 G.D. Searle & Co. LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use
WO1998006394A1 (en) * 1996-08-16 1998-02-19 Schering Corporation Treatment of upper airway allergic responses with a combination of histamine receptor antagonists
US5869479A (en) * 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses
US7364730B2 (en) 1998-04-21 2008-04-29 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften, E.V. Human K+ channel and prognosing applications thereof
US6638736B1 (en) 1998-04-21 2003-10-28 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Human K+ ion EAG channels
US7364845B2 (en) 1998-04-21 2008-04-29 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften, E.V. Human K+ channel and prognosing applications thereof
US7129207B2 (en) 1998-04-21 2006-10-31 Max-Planck-Gesellschaft Zur Forderung Wissenschaften E.V. Human K+ ion channel and therapeutic applications thereof
US7314914B2 (en) 1998-04-21 2008-01-01 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften, E.V. Human K+channel polypeptides
EP1347752A2 (en) * 2000-11-29 2003-10-01 Ramot at Tel-Aviv University Ltd. Anti-proliferative drugs
EP1347752A4 (en) * 2000-11-29 2005-04-06 Univ Ramot ANTI-PROLIFERATION DRUGS
AU2002218467B2 (en) * 2000-11-29 2006-07-13 Ramot At Tel-Aviv University Ltd. Anti-proliferative drugs
WO2003022258A1 (en) * 2001-09-10 2003-03-20 Ramot At Tel Aviv University Ltd. Aryloxypropylamines as chemosensitizing agent in the treatment of cancer
US6630454B2 (en) * 2001-09-10 2003-10-07 Ramot At Tel-Aviv University Ltd. Method and pharmaceutical composition for the treatment of cancer
WO2004022040A3 (en) * 2002-09-04 2004-04-29 Univ Manitoba Treatment of metastatic breast cancer with anthracyclines, taxanes and an histamine antagonist
WO2004022040A2 (en) * 2002-09-04 2004-03-18 The University Of Manitoba Treatment of metastatic breast cancer with anthracyclines, taxanes and an histamine antagonist
WO2012092114A2 (en) 2010-12-27 2012-07-05 The Curators Of The University Of Missouri Oxidosqualene cyclase as a protein target for anticancer therapeutics
EP2658544A2 (en) * 2010-12-27 2013-11-06 The Curators Of The University Of Missouri Oxidosqualene cyclase as a protein target for anticancer therapeutics
EP2658544A4 (en) * 2010-12-27 2014-05-28 Univ Missouri OXIDOSQUALENZYCASE AS A PROTEINT ARGET FOR ANTICIPATED THERAPEUTICS
AU2011352378B2 (en) * 2010-12-27 2016-08-04 The Curators Of The University Of Missouri Oxidosqualene cyclase as a protein target for anticancer therapeutics
US10143686B2 (en) 2010-12-27 2018-12-04 The Curators Of The University Of Missouri Oxidosqualene cyclase as a protein target for anticancer therapeutics
US10456388B2 (en) 2015-01-19 2019-10-29 Belina Pharma Ab Antihistamine for use in treatment of breast cancer

Also Published As

Publication number Publication date
JPH10182490A (ja) 1998-07-07
JP2834328B2 (ja) 1998-12-09
AU693780B2 (en) 1998-07-09
AU1480497A (en) 1997-05-15
KR960700698A (ko) 1996-02-24
AU6035294A (en) 1994-09-14
GB9303210D0 (en) 1993-03-31
JPH08506593A (ja) 1996-07-16
EP0684817A1 (en) 1995-12-06

Similar Documents

Publication Publication Date Title
US5747543A (en) Treatment method for cancer
AU693780B2 (en) Cancer treatment
TWI259077B (en) Combinations of drugs for the treatment of neoplastic disorders
US5650425A (en) Permanently ionic derivatives of steroid hormones and their antagonists
US5364843A (en) Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
US5998467A (en) Medicine for oculopathy
US5618846A (en) Treatment method for cancer
HU201731B (en) Process for producing substituted benzamides and pharmaceutical compositions comprising such active ingredient
EP1123702A1 (en) Analgesics
EP0682947B1 (en) Medicament for therapeutic and prophylactic treatment of diseases caused by smooth muscle cell hyperplasia
JPWO2005079845A1 (ja) 片頭痛予防薬
WO1989005795A1 (en) Novel antiarrhythmic agents ii
WO1989007441A1 (en) 6-amino-1,2-benzopyrone antitumorigenic agents and method
EP0563127B1 (en) Improved treatment method for cancer
US6284799B1 (en) Cancer treatment
AU749157B2 (en) Cancer treatment
CA2156162C (en) Cancer treatment
US5432168A (en) Method of treatment of hormone-unresponsive metastatic prostate cancer
JP6152387B2 (ja) Ｉ型およびｉｉ型糖尿病の処置
Bhatnagar et al. Recent Developments of Antipsychotic Drugs with Phenothiazine Hybrids: A Review.
SU1398771A3 (ru) Способ получени замещенных бензамидов
JP2001523717A (ja) 異常細胞増殖、下痢および白痢によって特徴付けられる鎌状細胞病、炎症性の疾病を治療または予防するための置換ジフェニルインダノン、インダンおよびインドール化合物の使用
WO2022192731A1 (en) Compositions and methods for treating anemia associated with a ribosomal disorder
KR820001235B1 (ko) 알킬티오페녹시프로파놀아민의 제조방법
JPH06507614A (ja) ２−アミノメチル−２，３−ジヒドロ−１，４−ベンゾジオキシンのｎ−アリールアルキル誘導体およびその製造方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB HU JP KP KR KZ LK LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2156162

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1994906813

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1994906813

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1996 505269

Country of ref document: US

Date of ref document: 19960223

Kind code of ref document: A

WWW Wipo information: withdrawn in national office

Ref document number: 1994906813

Country of ref document: EP